Human pituitary tumors of a gonadotroph cell origin represent up to 30% of all diagnosed pituitary neoplasms. Clinically, these tumors cause considerable morbidity because of mass effect, resulting in cranial nerve compression syndromes, including visual loss and other neurologic deficits, and there are no established adjunctive medical therapies to control tumor growth. A major finding regarding the pathogenesis of human pituitary tumors in our previous grant record period was that such tumors are monoclonal in origin, demonstrating that a somatic mutation is a requisite event in tumor formation. The next critical questions are what mechanisms underlie selective clonal proliferation in pituitary tumors, and what mechanisms underlie the pathogenesis of specific adenoma phenotypes. We have now isolated a pituitary-derived anti-proliferative gene PDAP, a novel gene which inhibits cell proliferation. This gene is expressed in normal human pituitary tissue but not in most human pituitary tumors as well as other human cancer cells. We propose to investigate the structure, function, and regulation of this novel gene as well as the mechanisms by which it suppresses tumor cell growth. We will characterize the gene structure of PDAP and investigate its promoter activities in normal and tumor cells. We will investigate the relationship between PDAP and cell growth. In addition, we will determine whether PDAP is expressed and functions in a cell type-specific manner in human pituitary. The discovery of a novel gene with antiproliferative effects is an exciting new finding. Investigation of the mechanism for the loss of PDAP expression in human tumors will provide important information regarding the pathogenesis of human pituitary adenomas, and, potentially, other human tumors.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK040947-14
Application #
7017712
Study Section
Biochemical Endocrinology Study Section (BCE)
Program Officer
Malozowski, Saul N
Project Start
1989-03-01
Project End
2008-07-31
Budget Start
2006-03-01
Budget End
2008-07-31
Support Year
14
Fiscal Year
2006
Total Cost
$441,804
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Chunharojrith, Paweena; Nakayama, Yuki; Jiang, Xiaobing et al. (2015) Tumor suppression by MEG3 lncRNA in a human pituitary tumor derived cell line. Mol Cell Endocrinol 416:27-35
Zhou, Yunli; Zhang, Xun; Klibanski, Anne (2014) Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma. Mol Cell Endocrinol 386:16-33
Zhou, Yunli; Zhang, Xun; Klibanski, Anne (2012) MEG3 noncoding RNA: a tumor suppressor. J Mol Endocrinol 48:R45-53
Cheunsuchon, Pornsuk; Zhou, Yunli; Zhang, Xun et al. (2011) Silencing of the imprinted DLK1-MEG3 locus in human clinically nonfunctioning pituitary adenomas. Am J Pathol 179:2120-30
Gordon, Francesca E; Nutt, Catherine L; Cheunsuchon, Pornsuk et al. (2010) Increased expression of angiogenic genes in the brains of mouse meg3-null embryos. Endocrinology 151:2443-52
Zhang, Xun; Gejman, Roger; Mahta, Ali et al. (2010) Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer Res 70:2350-8
Zhang, Xun; Rice, Kimberley; Wang, Yingying et al. (2010) Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions. Endocrinology 151:939-47
Zhang, Xun; Zhou, Yunli; Klibanski, Anne (2010) Isolation and characterization of novel pituitary tumor related genes: a cDNA representational difference approach. Mol Cell Endocrinol 326:40-7
Zhou, Yunli; Cheunsuchon, Pornsuk; Nakayama, Yuki et al. (2010) Activation of paternally expressed genes and perinatal death caused by deletion of the Gtl2 gene. Development 137:2643-52
Gejman, Roger; Batista, Dalia L; Zhong, Ying et al. (2008) Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 93:4119-25

Showing the most recent 10 out of 45 publications